Presentation for Earnings Call with Analysts/Instituitional Investors on Un-Audited Financials Results for the quater ended June 30, 2026

MedPlus Health Services Limited July 21, 2026 The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai – 400 051 BSE Scrip Code: 543427 NSE Symbol: MEDPLUS Dear Sir/ Madam, Sub: Presentation for Earnings Call with Analysts/Institutional Investors on Un-Audited Financial Results for the quarter ended June 30, 2026 Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our letter dated July 15, 2026 please find enclosed herewith the presentation for Earnings Call with Analysts/Institutional Investors on Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 scheduled to be held on Wednesday, July 22, 2026 at 16:00 Hrs. (IST). The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Thanking You Yours faithfully For MedPlus Health Services Limited Gangadi Madhukar Reddy Managing Director and CEO (DIN: 00098097) Encl: a/a 040-6724 6724 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com MEDPLUS HEALTH SERVICES LIMITED Q1 FY2027 INVESTOR PRESENTATION July 2026 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by MedPlus Health Services Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. The MedPlus Story e Marked presence of 20 years with network of 5,450+ Stores Spread across O 13 states and 1 union territory Cluster based expansion strategy: ‘Continue 2nd Largest Pharma Retailer in the country deeper penetration vs. with pioneer in omni channel Wider reach’ Well curated SKU’s at Outlets and 30k+ Employees ~51k SKU’s across warehouses Store level Unit economics with ROCE of over 60% Serving the Customers of ~850 Cities ~1,470 Outlets which are < 24M, upon maturity are P&L accretive Q1FY27 2 t a Q1 FY2027 Highlights (1/2) ₹ 18,796m Revenue ₹ 4,603m Gross Margin • ₹ 3,370m increase over Q1FY26 • 24.5% GM%, lower by 160 bps yoy, 21.8% yoy lower by 200 bps qoq • ₹ 152m increase over Q4FY26 0.8% qoq • 1.5% decrease in private label over Q1FY26 146 Store Net Additions Stores > 12 months • 222 gross additions • 15.3% revenue growth over Q1FY26 • 125 net additions beyond Tier-One • 10.4% Store Level EBITDA margin • 5,476 stores as on 30-June-26 • 63.0% Store Level Operating ROCE ₹ 588m Pharmacy Operating ₹ 1,252m Operating Cash EBITDA Flow • 3.2% Operating EBITDA margin in • 192.2% OCF/ Operating EBITDA Pharmacy (lower by 240 bps qoq) • ₹ 6,219m closing cash & bank • ₹ 651m Company Operating EBITDA balance Q1FY27 3 t a Q1 FY2027 Highlights (2/2) R Revenue, ₹m Gross Margin Operating EBITDA EBITDA, ₹m 18,644 18,796 5.8% 18,061 26.1% 26.1% 26.2% 26.5% 5.3% 5.4% 1,898 d 1,769 e 16,793 24.5% 4.7% 1,663 1,531 t 1,457 a 15,426 3.5% l o 1,076 s 887 o 651 18,266 18,399 1,803 17,715 1,688 25.3% 5.6% 1,616 25.0% 25.0% 25.1% 5.1% 5.2% 1,420 1,426 16,440 4.6% y 23.3% a 15,106 3.2% r 1,022 a 925 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Operating EBITDA ₹m Operating EBITDA margin Q1FY27 4 Cluster Based Network Enables Profitable Omni-Channel Service Stores As On Jun-26 Strong Cluster Based Network Strong network of 5,476 stores across Metros, Tier-One, Tier-Two and beyond. 5,476 stores 2- hour delivery Ability to service 100% market – acute + chronic Online only players cannot match this As opposed to online only players that 1 proposition given lack of hyperlocal largely cater to only chronic segment store presence 1 (37%1 of the market) 48 758 189 Lower delivery costs 620 Lower customer acquisition cost Because of the hyperlocal presence of As existing stores act as branding sites MedPlus’ 5,476 stores 1040 1118 41 1. For 2020; Proportion of domestic pharmaceutical market. Technopak Advisors (2021). Pharmacy Retail in India Metro Tier-One 2. Stores in Puducherry and Delhi are not represented in the map above. As on 30-Jun-26 we have 6 stores Powered by Bing © GeoNames, Microsoft, TomTom in Puducherry and 1 store in Delhi Tier-Two Tier-Three+ Q1FY27 5 Scale Allows A Large Private Label Basket: 1550+ SKUs Pharma Over 900 products covering Chronic, Acute, OTC & Other Pharmaceutical products Non-Pharma Over 650 products covering, packaged food, baked goods, dry goods, cleaning products, cosmetics and toiletries Q1FY27 6 Poised for Growth Key Pillars Of Growth MedPlus has an established base of operations in 13 states and 1 union territory. Therefore, we will: Growth in existing clusters and • Further grow in cities where we have market leadership. Metro and Tier - One followed develop new clusters by Tier - Two and beyond • Replicate our leadership in markets where we have entered but yet to attain market leadership MedPlus has built an extensive in-house technology platform. On the back of that, we will: Leverage our leadership in • Expand our target addressable market via omni-channel offering omni-channel • Increase retention via omni-channel • Operationally extend <2 hour delivery to more locations MedPlus has a curated private label range of 1550+ SKUs. [Showing first 8,000 characters — download PDF for full document]